Production of J&J’s COVID-19 vaccine at the Baltimore site was halted by U.S. authorities in April following a discovery that ingredients from AstraZeneca (NASDAQ:AZN)’s COVID-19 vaccine, also being produced at the plant at that time, contaminated a batch of J&J’s vaccines.
J&J, Emergent and the FDA did not immediately respond to Reuters requests for comment.
